Hikma Pharmaceuticals (LON:HIK) Reaches New 12-Month Low - What's Next?

Key Points

• Hikma Pharmaceuticals reached a new 12-month low, trading at GBX 1,686 ($22.74) before closing at GBX 1,695 ($22.87) with significant trading volume.
• Recent analyst ratings indicate a mixed outlook, with JPMorgan and Deutsche Bank lowering their price targets, while Jefferies maintained a "buy" rating and a target of GBX 2,600.
• Insider activity has been notable, with the purchase of 200,000 shares by Mazen Darwazah at GBX 1,756 per share, indicating confidence from company insiders.

Hikma Pharmaceuticals PLC (LON:HIK - Get Free Report)'s stock price reached a new 52-week low on Monday . The stock traded as low as GBX 1,686 ($22.74) and last traded at GBX 1,695 ($22.87), with a volume of 326848 shares. The stock had previously closed at GBX 1,722 ($23.23).

Wall Street Analyst Weigh In

Several equities analysts recently commented on HIK shares. JPMorgan Chase & Co. dropped their price objective on shares of Hikma Pharmaceuticals from GBX 2,600 to GBX 2,500 and set an "overweight" rating for the company in a research note on Friday, August 8th. Jefferies Financial Group reiterated a "buy" rating and set a GBX 2,600 price objective on shares of Hikma Pharmaceuticals in a research report on Thursday, August 7th. Finally, Deutsche Bank Aktiengesellschaft dropped their price objective on shares of Hikma Pharmaceuticals from GBX 3,100 to GBX 2,850 and set a "buy" rating on the stock in a research note on Tuesday, August 12th. Four research analysts have rated the stock with a Buy rating, Based on data from MarketBeat, Hikma Pharmaceuticals currently has an average rating of "Buy" and an average target price of GBX 2,627.50.

Hikma Pharmaceuticals Stock Down 1.3%

The firm's fifty day moving average is GBX 1,893.40 and its 200 day moving average is GBX 1,980.76. The firm has a market cap of £3.76 billion, a P/E ratio of 1,017.37, a P/E/G ratio of 2.38 and a beta of 0.41. The company has a debt-to-equity ratio of 55.82, a quick ratio of 1.27 and a current ratio of 1.66.

Insider Activity at Hikma Pharmaceuticals

In related news, insider Mazen Darwazah purchased 200,000 shares of the firm's stock in a transaction on Thursday, August 7th. The shares were acquired at an average price of GBX 1,756 per share, for a total transaction of £3,512,000. Also, insider Laura Balan Balan bought 3,500 shares of the firm's stock in a transaction that occurred on Friday, August 22nd. The shares were purchased at an average cost of GBX 1,821 per share, with a total value of £63,735. 17.76% of the stock is owned by company insiders.

About Hikma Pharmaceuticals

At Hikma we help put better health within reach, every day. By creating high-quality medicines and making them accessible to the people who need them, we help to shape a healthier world that enriches all our communities. We help deliver this by living our culture, delivering our strategy, and acting responsibly.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.